BRAIN AF

Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF

This is a prospective, multicenter, randomized, double-blinded clinical trial exploring the efficacy and safety of rivaroxaban as compared to standard of care in reducing stroke, transient ischemic attack (TIA) and neurocognitive decline, in subjects with non-valvular AF and with low risk of stroke.

Enrollment Criteria

Inclusion
- 30-60 years old
- 30+ sec. documented Non-valvular AF in past 12 months
- Low risk of stroke as defined by the absence of:
- CHF (NYHA 2+)
- Prior CVA/TIA
- HTN
- DM
Exclusion
- Known dementia/depression past 1 year
- Hx internal bleeding/ulcer
- Surgery past 1 m. or planned
- Planned PVI or absence of recurrence of AF 3 months after PVI
- Cancer or Rad. Tx
- Creatinine clearance 30 mL/min or less
- Acute liver disease
- (ALT >3 times the upper limit of normal)
- Anemia/thrombocytopenia
- Pregnant/breastfeeding